Pharmaceuticals, Biotechnology and Life Sciences
– More than twice as many babies (61% vs. 29%) were able to sit without support for at least five…
– Genentech is also close to completing enrollment of a global randomized, double-blind, placebo-controlled Phase III clinical trial of Actemra…
– Tecentriq’s fourth indication in metastatic non-small cell lung cancer and fifth indication in lung cancer overall – – Approval…
– Satralizumab represents a potential new approach to treating neuromyelitis optica spectrum disorder (NMOSD), a rare, debilitating disease often misdiagnosed…
Genentech’s Tecentriq’s First Phase III cancer immunotherapy study to show an improvement in overall survival and progression-free survival for the…
Genentech has received FDA’s approval of Xofluza, which is the first and only antiviral medicine indicated specifically for patients at…
Genentech’s study reinforces efficacy and safety of Rituxan for treatment of PV, a rare autoimmune condition characterized by blistering of the skin and mucous membranes, showing that 40% of patients with pemphigus vulgaris (PV) achieved sustained complete remission, without the use of steroids for 16 weeks or more, when treated with Rituxan compared to 9.5% of patients on mycophenolate mofetil.
– IMvigor130 is the first positive Phase III study of a cancer immunotherapy combination in people with previously untreated advanced…
FDA has approved Genentech’s Rituxan as the first and only FDA-approved treatment for pediatric patients 2 years of age and older living with granulomatosis with polyangiitis or microscopic polyangiitis. Genetech noted that this approval is the first pediatric indication for Rituxan.
– Phase III IMpower110 study showed Tecentriq monotherapy helped people with advanced non-small cell lung cancer (NSCLC) with high PD-L1…